Global Blood Therapeutics reports Q3 EPS (83c), consensus (86c)
Cash, cash equivalents and marketable securities totaled $482.1 million at September 30, 2018, compared with $329.4 million at December 31, 2017."Voxelotor has the potential to be a transformative treatment for the sickle cell community. We remain in active discussions with the U.S. Food and Drug Administration regarding the potential for accelerated approval of voxelotor. We continue to believe that voxelotor meets the standard for accelerated approval based on the statistically significant and clinically meaningful increase in hemoglobin and reduction in hemolysis," said Ted W. Love, M.D., president and chief executive officer of GBT. "Our guidance remains that we expect to provide a regulatory update by the end of this year. Additionally, we look forward to reporting an expanded data set from Part A of the HOPE Study and data from the 1500 mg cohort of the HOPE-KIDS 1 Study at the American Society of Hematology Annual Meeting later this year."